Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 4/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MYC | P01106 | 1/20 | 0.33 |
| ▸ | PDE6A | P16499 | 1/20 | 0.33 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.32 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.32 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.32 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12210495 | 0.91 | KDM4E (0.38) | PDE5AKDM4EHSD17B10MAPK14ALDH1A1 | |
| SCHEMBL13273928 | 0.90 | HSP90AA1 (0.37) | PDE5AKDM4EHSD17B10MAPK14ALDH1A1 | |
| SCHEMBL15061690 | 0.88 | PDE5A (0.35) | PDE5AKDM4EHSD17B10MAPK14ALDH1A1 | |
| SCHEMBL15060786 | 0.85 | ACSS2 (0.40) | KDM4EMAPK14ACSS2MEN1TSHR | |
| SCHEMBL12210252 | 0.83 | KDM4E (0.35) | PDE5AKDM4EHSD17B10MAPK14ALDH1A1 | |
| SCHEMBL18404505 | 0.83 | POLB (0.35) | PDE5AKDM4EMAPK14ALDH1A1MAPK13 | |
| SCHEMBL15060782 | 0.81 | KDM4E (0.35) | KDM4EHSD17B10ALDH1A1SMN1; SMN2MYC | |
| SCHEMBL13273917 | 0.80 | PPARG (0.41) | PDE5AKDM4EHSD17B10ALDH1A1SMN1; SMN2 | |
| SCHEMBL15060788 | 0.80 | KDM4E (0.37) | PDE5AKDM4EHSD17B10MAPK14ALDH1A1 | |
| SCHEMBL15060795 | 0.78 | MTNR1A (0.34) | PDE5AKDM4EHSD17B10SMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130303535-A1 | NOVEL BICYCLIC HETEROCYCLIC COMPOUND | Sumitomo Pharma Co., Ltd. (JP) | 2013-11-14 | — | — | US | disclosed |
| US-20130303535-A1 | NOVEL BICYCLIC HETEROCYCLIC COMPOUND | Sumitomo Pharma Co., Ltd. (JP) | 2013-11-14 | — | — | US | disclosed |
| US-8471038-B2 | Bicyclic heterocyclic compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2013-06-25 | — | — | US | disclosed |
| US-8471038-B2 | Bicyclic heterocyclic compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2013-06-25 | — | — | US | disclosed |
| US-20110294804-A1 | NOVEL BICYCLIC HETEROCYCLIC COMPOUND | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-12-01 | — | — | US | disclosed |
| US-20110294804-A1 | NOVEL BICYCLIC HETEROCYCLIC COMPOUND | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294804-A1 | NOVEL BICYCLIC HETEROCYCLIC COMPOUND | OPRL1, SCN1B, OPRD1 | PDE5A 1986/4885KDM4E 2976/4885HSD17B10 3240/4885 |
| US-20130303535-A1 | NOVEL BICYCLIC HETEROCYCLIC COMPOUND | OPRL1, SCN1B, OPRD1 | PDE5A 1986/4885KDM4E 2976/4885HSD17B10 3240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.